Millennium Management
PGNX

Millennium Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Millennium Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-22,858
Closed -$115K – 4840
2019
Q3 		$115K Sell
22,858
-59,446
-72% -$296K ﹤0.01% 3942
2019
Q2 		$508K Sell
82,304
-230,331
-74% -$1.11M ﹤0.01% 3224
2019
Q1 		$1.45M Sell
312,635
-236,318
-43% -$1.07M ﹤0.01% 2631
2018
Q4 		$2.31M Buy
+548,953
New +$2.8M ﹤0.01% 2112
2018
Q3 		– Sell
-119,350
Closed -$960K – 4468
2018
Q2 		$960K Buy
119,350
+90,400
+312% +$690K ﹤0.01% 2862
2018
Q1 		$216K Buy
28,950
+565
+2% +$3.76K ﹤0.01% 3348
2017
Q4 		$169K Buy
+28,385
New +$172K ﹤0.01% 3568
2017
Q3 		– Sell
-91,911
Closed -$624K – 4044
2017
Q2 		$624K Sell
91,911
-174,548
-66% -$1.29M ﹤0.01% 2699
2017
Q1 		$2.52M Sell
266,459
-68,211
-20% -$681K ﹤0.01% 1874
2016
Q4 		$2.89M Sell
334,670
-2,079,038
-86% -$15.4M 0.01% 1666
2016
Q3 		$15.3M Buy
2,413,708
+150,711
+7% +$911K 0.03% 701
2016
Q2 		$9.55M Sell
2,262,997
-393,954
-15% -$1.9M 0.02% 878
2016
Q1 		$11.6M Buy
2,656,951
+386,226
+17% +$1.72M 0.03% 739
2015
Q4 		$13.9M Sell
2,270,725
-9,698
-0.4% -$63.6K 0.03% 743
2015
Q3 		$13M Buy
2,280,423
+275,897
+14% +$2.12M 0.03% 790
2015
Q2 		$15M Buy
2,004,526
+1,641,729
+453% +$9.93M 0.03% 758
2015
Q1 		$2.17M Sell
362,797
-5,726
-2% -$36K ﹤0.01% 1897
2014
Q4 		$2.79M Buy
+368,523
New +$2.2M 0.01% 1746
2014
Q3 		– Sell
-132,156
Closed -$570K – 4138
2014
Q2 		$570K Buy
+132,156
New +$505K ﹤0.01% 2522
2014
Q1 		– Sell
-87,535
Closed -$467K – 4060
2013
Q4 		$467K Buy
+87,535
New +$385K ﹤0.01% 2757
2013
Q3 		– Sell
-33,877
Closed -$151K – 3684
2013
Q2 		$151K Buy
+33,877
New +$152K ﹤0.01% 2819

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management's PGNX Position: Q4 2019 in Review

Millennium Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 22,858 shares — an estimated $115K sold.

Millennium Management first reported a position in PGNX in Q2 2013 and held it in 21 quarters. The position peaked at $15.3M in Q3 2016. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Millennium Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Millennium Management sold 22,858 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $115K.
  • Millennium Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 21 quarters.
  • Millennium Management's Progenics Pharmaceuticals Inc position peaked at $15.3M in Q3 2016.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Millennium Management's 13F filing for Q4 2019, filed 14 Feb 2020.